antibody

CD79a

MBS370041

5 + Control Slides

115 USD

monoclonal

mouse

nonconjugated

JCB117

human, dog

Antibody

CD79a

CD79a

CD79a; B-cell antigen receptor complex-associated protein alpha chain; B-cell antigen receptor complex-associated protein alpha chain; ig-alpha; MB-1 membrane glycoprotein; surface IgM-associated protein; CD79a antigen (immunoglobulin-associated alpha); membrane-bound immunoglobulin-associated protein; CD79a molecule, immunoglobulin-associated alpha; Ig-alpha; MB-1 membrane glycoprotein; Membrane-bound immunoglobulin-associated protein; Surface IgM-associated protein

CD79a

CD79A; CD79A; IGA; MB-1; IGA; MB1

CD79A_HUMAN

Monoclonal

IgG1/K

JCB117

Mouse

Human, Dog, Cat

CD79a is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.

Store at 2 to 8 degree C in the dark.

Control: Tonsil, Lymph Node. Localization: Membranous

Reactivity Note: Paraffin, Frozen

CD79a is non-covalently associated with membrane-bound immunoglobulins on B-cells to constitute the B-cell Ag receptor. CD79a first appears at pre B-cell stage and persists until the plasma-cell stage, where it is found as an intracellular component. CD79a is found in the majority of Acute Leukemias of precursor B-cell type, in B-cell lines, B-cell Lymphomas, and in some Myelomas. CD79a is a B-cell marker that is generally used to complement CD20. This antibody will stain many of the same Lymphomas as CD20, but also stains more B-precursor Lymphoid Leukemias than CD20. CD79a also stains more cases of Plasma-cell Myeloma and occasionally some types of endothelial cells as well. CD79a will stain many cases of Acute Promyelocytic Leukemia (FAB-M3), but only rarely stains other types of Myeloid Leukemia.

1087007

P11912

25,038 Da

B Cell Receptor Signaling Pathway (198909); B Cell Receptor Signaling Pathway (83081); B Cell Receptor Signaling Pathway (492); BCR Signaling Pathway (138058); Primary Immunodeficiency Pathway (83125); Primary Immunodeficiency Pathway (537)

The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-alpha protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq]

Function: Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B cells. Ref.13 Ref.14. Subunit structure: Heterodimer of alpha and beta chains; disulfide-linked. Part of the B-cell antigen receptor complex where the alpha/beta chain heterodimer is non-covalently associated with an antigen-specific membrane-bound surface immunoglobulin of two heavy chains and two light chains. Interacts through its phosphorylated ITAM domain with the SH2 domains of SYK which stimulates SYK autophosphorylation and activation. Also interacts, when phosphorylated on Tyr-210, with the SH2 domain of BLNK/SLP65, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK which is necessary for trafficking of the BCR to late endosomes. Interacts with Src-family tyrosine kinases including FYN and LYN, increasing their activity. Subcellular location: Cell membrane; Single-pass type I membrane protein. Note: Following antigen binding, the BCR has been shown to translocate from detergent-soluble regions of the cell membrane to lipid rafts although signal transduction through the complex can also occur outside lipid rafts. Tissue specificity: B-cells. Post-translational modification: Phosphorylated on tyrosine, serine and threonine residues upon B-cell activation. Phosphorylation of tyrosine residues by Src-family kinases is an early and essential feature of the BCR signaling cascade. The phosphorylated tyrosines serve as docking sites for SH2-domain containing kinases, leading to their activation which in turn leads to phosphorylation of downstream targets. Phosphorylation of serine and threonine residues may prevent subsequent tyrosine phosphorylation. Ref.16. Involvement in disease: Defects in CD79A are the cause of agammaglobulinemia type 3 (AGM3) [. MIM:613501]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life. Note=Two different mutations, one at the splice donor site of intron 2 and the other at the splice acceptor site for exon 3, have been identified. Both mutations give rise to a truncated protein. Ref.15 Ref.17. Sequence similarities: Contains 1 Ig-like C2-type (immunoglobulin-like) domain.Contains 1 ITAM domain.

5 + Control Slides

115 USD

3 ml (Prediluted)

175

0.1 mL (Concentrate)

185

7 ml (Prediluted)

250

0.5 mL (Concentrate)

375